Shares of AIM VACCINE Co Ltd (06660.HK) surged as much as 6.55% on Tuesday morning after the biopharmaceutical company announced that its mRNA respiratory syncytial virus (RSV) vaccine candidate has obtained approval from China's National Medical Products Administration (NMPA) to proceed to clinical trials.
RSV is a major cause of respiratory illness in infants and the elderly. Successful development of an effective vaccine against this virus would represent a significant medical breakthrough and commercial opportunity for AIM VACCINE.
The positive regulatory development for AIM VACCINE's RSV vaccine program appears to be the primary driver behind the strong stock price rally today. Investors are betting that this product candidate has a higher probability of eventual market approval and sales following the green light to initiate human clinical studies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。